Short Daily Versus Conventional Hemodialysis for COVID-19 Patients

COVID-19 Clinical Trial

Official title:

Short Daily Versus Conventional Hemodialysis for COVID-19 Patients: A Randomized Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05212675
• Other study ID #: SBMU-1400-10
• Status: Completed
• Phase: N/A
• Start date: March 1, 2021
• Est. completion date: August 30, 2021

Study information

• Verified date: January 2022
• Source: Shahid Beheshti University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment of dialysis patients involved with COVID-19 with short daily hemodialysis has been supposed to improve short term outcome. It is unclear if short daily dialysis would optimize mortality or ICU admission in routine dialysis patients with COVID-19.

Also the potential variants according with worse outcomes remain to be fully elucidated.

Description:

investigators undertook a randomized trial in ESRD patients infected with COVID-19 to determine: 1) if short-daily hemodialysis is associated with a reduction in mortality and ICU admission in one weak period and; 2) the potential effective variants in worst outcome. . Paperwork for the trial was submitted to the shaheed beheshti university of medical sciences in June 2021 for registration . The protocol for this trial and supporting CONSORT checklist are available. The SBMU Ethics Board approved the study and all amendments. The study was conducted according to the Declaration of Helsinki.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: August 30, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• ESRD patients >3months on hemodialysis admitted for COVID-19

Exclusion Criteria:

• ESRD patients <3 months on hemodialysis infected with COVID-19

Related Conditions & MeSH terms

• COVID-19

Intervention

Other:
• Short daily dialysis
7 days 2hours dialysis

Locations

Country	Name	City	State
Iran, Islamic Republic of	Nooshin Dalili	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
Shahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	discharged or dead	From date of randomization until the date of first documented progression or date of death
Primary	ICU add	admission to ICU or not	From date of randomization until the date of first documented progression or date of death